Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RTX-800
- Development stage
- Preclinical
- Lead developer
- Resonant Therapeutics
- Modality
- Antibody-Based Therapeutics
01
Overview
RTX-800 is a drug candidate developed by Resonant Therapeutics, Inc. It is currently in preclinical development for various indications, including glioma, ovarian cancer, and other neoplasms, as well as nervous system diseases, endocrinology and metabolic diseases, and urogenital diseases. The drug is an antibody, consistent with Resonant Therapeutics' platform which focuses on discovering novel, highly selective anti-tumor antibodies that target the tumor microenvironment. The specific mechanism of action and target for RTX-800 have not been publicly disclosed, but it is part of a pipeline of antibody-based therapeutics designed to address difficult-to-treat tumors.
Beyond the preview
Go deeper on RTX-800.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RTX-800.